about
Receptor for advanced glycation end products and its involvement in inflammatory diseasesBoth Ca2+ and Zn2+ are essential for S100A12 protein oligomerization and functionDo advanced glycation end-products play a role in malaria susceptibility?RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesisCurrent perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementThe effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient miceThe proinflammatory RAGE/NF-κB pathway is involved in neuronal damage and reactive gliosis in a model of sleep apnea by intermittent hypoxiaReceptor for advanced glycation end products is detrimental during influenza A virus pneumonia.Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis.RAGE supports parathyroid hormone-induced gains in femoral trabecular boneDiabetes-induced alterations in the extracellular matrix and their impact on myocardial function.Insulin glycation by methylglyoxal results in native-like aggregation and inhibition of fibril formationAnti-RAGE antibody ameliorates severe thermal injury in rats through regulating cellular immune function.Rs1800625 in the receptor for advanced glycation end products gene predisposes to sepsis and multiple organ dysfunction syndrome in patients with major trauma.RAGE controls leukocyte adhesion in preterm and term infantsOn the significance of new biochemical markers for the diagnosis of premature labour.RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization.The receptor for advanced glycation end products (RAGE) contributes to the progression of emphysema in miceHuman eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100BSoluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor.Association between the Advanced Glycosylation End Product-Specific Receptor Gene and Cardiovascular Death in Older MenThe pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in miceRAGE signaling contributes to neuroinflammation in infantile neuronal ceroid lipofuscinosisTargeting RAGE in sepsis.Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.Diagnostic Potential of Evaluation of SDF-1α and sRAGE Levels in Threatened Premature Labor.The receptor RAGE: Bridging inflammation and cancerS100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.Neuroinflammation and copper in Alzheimer's disease.RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?The role of receptor for advanced glycation endproducts (RAGE) in infection.Receptor for advanced glycation end products (RAGE) and its ligands: focus on spinal cord injury.Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia.The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion.Soluble and Endogenous Secretory Receptors for Advanced Glycation End Products in Threatened Preterm Labor and Preterm Premature Rupture of Fetal MembranesThe Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction.The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness.Reduced Susceptibility to Sugar-Induced Metabolic Derangements and Impairments of Myocardial Redox Signaling in Mice Chronically Fed with D-Tagatose when Compared to Fructose
P2860
Q21285070-AD70B308-2988-4AE4-B6A1-D4FEF2F1926FQ24318378-7C9AD5FC-79D2-4B2D-839E-6706F638B230Q24471760-B0F966FE-E7BF-4503-A839-BFDA76E4E921Q24658378-843F547F-8920-4D5F-9EDF-97EADAF1E04DQ26781156-02E523EE-1CC0-4B67-8BC6-6AA80F29480FQ28535046-627E1ECC-C0E0-4FD6-97D3-9CA7DC330FFBQ28543363-94D010D6-000F-405D-96CC-0B0FB95E8E00Q30378823-A2E4EC38-BE58-499E-9D08-C1E737ADC2CFQ30412055-2E93FAEA-90B7-4306-92AF-FE2B4055A497Q33520403-D5C9818B-1FDC-4758-A2D2-DA4EE5DEB1DFQ33711031-2BEF436D-D4FE-4229-86A4-B86F98869973Q33984004-D8F26EDE-E952-4B23-8171-43CFCFE8DB68Q34138346-B7EA5B43-96D9-40D4-9DC4-FC0CC5028833Q34457310-7D996FE4-1C2F-424A-B991-59B2D88AF6FAQ34636067-3D8613D8-B60D-4E36-940C-0EB250661373Q34762626-070C92B1-9391-4796-BB0C-1FCFBCEA5313Q35107593-F74BF348-9512-4BB3-9025-41CE8809DF77Q35190905-828996DE-5DFA-4095-B6CE-4D4CE77475E1Q35579991-AC3B60F7-CAEC-4DE6-A23D-21C99C19CD0AQ35658848-E29C3699-85F2-4C39-A880-046C1A03BA48Q35727237-B1854F74-D4BB-4146-824B-DC9A29BBEA9EQ36800611-D3591EA9-A186-4CDF-A3B4-8F21E2A87018Q37003028-9A8404C1-0A68-4969-8138-A7269003B199Q37078482-E3021731-B1ED-4233-942D-8F738272899EQ37084522-328BC154-B77C-487D-973C-FD396813B072Q37172011-8948AC97-6299-4599-9EA7-0BE8FD77848EQ37212720-F23A31AA-0B26-4E8F-B0CA-3409B9E2679EQ37354472-FD77AA1B-1282-4DA6-9DFC-55F0E46399B1Q37393152-118A3AAC-3F46-4662-8E92-68E8681BCD22Q37455857-436FF80C-E826-42C6-BFBF-0FC32AFE3B3EQ37860412-10E48A1D-8D59-4D9D-A5BB-CC6094461A1BQ38234624-18613BE2-3AE9-4CEB-9BC7-292B7656F127Q39727356-9BAEA00F-6C40-4FE0-B73A-3E1505F3CA71Q40584885-4F3A9FA5-49BA-4D7E-B902-4672EA996D57Q40977776-4DE5ACBA-2FB0-424A-BA19-8460466F0326Q41980641-FF4D8705-00DA-4131-B7C1-35BFA35AB319Q48244517-DD59945B-69E5-4E0F-B553-071CDAD8EE6EQ57493002-6B3C88B3-0F0A-4A77-9551-E5C25C1C6BB7
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
RAGE in inflammation: a new therapeutic target?
@ast
RAGE in inflammation: a new therapeutic target?
@en
type
label
RAGE in inflammation: a new therapeutic target?
@ast
RAGE in inflammation: a new therapeutic target?
@en
prefLabel
RAGE in inflammation: a new therapeutic target?
@ast
RAGE in inflammation: a new therapeutic target?
@en
P2093
P1476
RAGE in inflammation: a new therapeutic target?
@en
P2093
Angelika Bierhaus
David M Stern
Peter P Nawroth
P304
P577
2006-11-01T00:00:00Z